Navigation Links
QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Date:7/26/2010

BEDMINSTER, N.J. and SYDNEY, July 26 /PRNewswire-FirstCall/ -- QRxPharma (ASX: QRX and Pink Sheets: QRXPY) reported today positive outcomes of its European Scientific Advice meetings on the development and registration of MoxDuo IR, an immediate release Dual-Opioid™ pain therapy. The Company is currently completing pivotal Phase 3 trials required for filing a New Drug Application (NDA) for MoxDuo IR with the United States Food and Drug Administration (FDA). QRxPharma intends to submit a Marketing Authorisation Application (MAA) in Europe, the second largest market (approximately US$3.5 billion) in the world for opioid analgesics. In support of these registration activities, the Company held Scientific Advice meetings in Germany and the United Kingdom in May 2010. Based on the positive responses in the official minutes of these meetings, QRxPharma intends to select Germany as the lead Agency for European MAA review, and will submit the application in 2011.

"Similar to the FDA's acceptance of our streamlined development plan for MoxDuo IR, feedback and guidance from the European Agencies regarding the suitability of our data package for MAA submission is also positive," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "Our objective is to launch MoxDuo IR globally in 2012, and this feedback clears a significant hurdle and facilitates our European regulatory and commercialisation strategy."

In reply to questions posed by QRxPharma to the German Federal Institute for Drugs and Medical Devices (BfArM), the data package available from the U
'/>"/>

SOURCE QRXPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Reportlinker.com announces that a new market research report ... America Aesthetic Lasers and Energy Devices Market Outlook ... North America Aesthetic Lasers and Energy ... GlobalData,s new report, "North America Aesthetic Lasers and ... market data on the North America Aesthetic Lasers ...
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... is available in its catalogue: Germany ... 2020 http://www.reportlinker.com/p02343442/Germany-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html ... Outlook to 2020 Summary GlobalData,s new ... Outlook to 2020", provides key market data on ...
(Date:8/28/2014)... -- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – ... - http://photos.prnewswire.com/prnh/20140828/140879 ) The ... Poland " an essential source of information and ... and provides insights into the demographic, regulatory, reimbursement ... provides valuable insights into the trends and segmentation ...
Breaking Medicine Technology:North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 9Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5
... 8, 2011 PermaDerm™, an engineered skin substitute which ... prepared from a patient,s own skin cells, has been ... that the U.S. Department of Defense awarded more than ... of the therapeutic candidate for the treatment of severe ...
... a Carmel-headquartered software development and solutions firm has been ... 500 and mid-market businesses throughout the world since 1983. ... its extensive supply chain experience to develop supply chain ... Blue Horseshoe Intellectual Property (BHIP). Led ...
Cached Medicine Technology:PermaDerm™ Receives National Media Coverage 2Software Development Firm's New Intellectual Property Group, Blue Horseshoe IP Creates Solutions to Help Customers Optimize Supply Chain 2Software Development Firm's New Intellectual Property Group, Blue Horseshoe IP Creates Solutions to Help Customers Optimize Supply Chain 3
(Date:8/29/2014)... (PRWEB) August 29, 2014 Evolutions Medical ... Barbara in the Santa Barbara News-Press Readers’ Choice 2014 ... the Readers’ Choice poll as Best Medical Spa. The ... reads the following about Evolutions Medical Spa recognition: , ... it is recognized as a top-notch, cutting-edge medical spa ...
(Date:8/29/2014)... COLUMBUS, Ohio (PRWEB) August 29, 2014 ... vice president of operations & business development. , Rees ... the vice president of business development. , A wholly ... (OPRS), Senior Independence provides older adults with options, including ... teams, in-home care (e.g., meal preparation) and therapeutic adult ...
(Date:8/29/2014)... Last week, the Fed reported ... gain. Industrial production rose to 0.4% while manufacturing output progressed ... the single largest boost since February this year. Capacity use ... February as well – an increase that could be attributed ... a 79.2% rate, which is a measure of slack across ...
(Date:8/29/2014)... have been hospitalized for a burn as a child experience ... to new research at the University of Adelaide . ... been conducted by the University,s Centre for Traumatic Stress Studies. ... some form of mental illness and 30% suffered depression at ... in the journal Burns , also found ...
(Date:8/29/2014)... New ESC registries are being launched on cardiac ... comes as the long-term phase of the cardiomyopathy ... failure patients conducted in collaboration with the Organisation ... outcomes evaluation. , The registries are all part ... Professor Roberto Ferrari, Chairperson of EORP, said: "The ...
Breaking Medicine News(10 mins):Health News:Evolutions Named Best Medical Spa in Santa Barbara by Santa Barbara News Press 2Health News:Evolutions Named Best Medical Spa in Santa Barbara by Santa Barbara News Press 3Health News:Senior Independence Promotes Rees to Vice President of Operations & Business Development 2Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 2Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 3Health News:Intervention needed for survivors of childhood burns 2Health News:New ESC registries launched on cardiac oncology and ACS 2Health News:New ESC registries launched on cardiac oncology and ACS 3Health News:New ESC registries launched on cardiac oncology and ACS 4
... diminished ovarian reserve producing viable eggs, study suggests ... may reduce fertility in breast cancer survivors, according ... Dana-Farber Cancer Institute. , They found that premenopausal ... were more likely than women who,d never had ...
... in young children has been linked to a significant ... FDA to recommend against their use for children less ... and efficacy, there has been little research on patterns ... children. Now, a new study from the Emergency Medicine ...
... one expert notes problems with manufacturing, unreliable delivery of ... Skin patches that contain the drug rotigotine help relieve ... , Dopaminergic drugs -- which stimulate the ... first-line treatment for RLS, and rotigotine is already used ...
... Aurora Medical Group, one of only 11 members ... ... Jeffrey W. Bailet, MD, of Lake,Geneva, has been appointed to the ... http://www.newscom.com/cgi-bin/prnh/20080530/AQF042 ), Dr. Bailet, an otolaryngologist, is a senior vice ...
... 3, 2008 at 8:30 a.m. ET - ... - First quarter 2008 net sales increased 20.2% year-over-year to $87.5 ... million,- Net beds served increased 8.5% year-over-year to 65,700 at March ... - Stock symbol changed ...
... Biologic use is expected to enhance quality of treatment ... -- The use of biologics is the focus of ... psoriasis and psoriatic arthritis released by the American Academy ... or infusion -- are systemic medications that pinpoint immune ...
Cached Medicine News:Health News:Chemo May Limit Fertility in Breast Cancer Survivors 2Health News:Study examines cold medication use in young children 2Health News:Rotigotine Skin Patch May Ease Restless Legs Symptoms 2Health News:Chem Rx Corporation Reports First Quarter 2008 Financial Results 2Health News:Chem Rx Corporation Reports First Quarter 2008 Financial Results 3Health News:Chem Rx Corporation Reports First Quarter 2008 Financial Results 4Health News:Chem Rx Corporation Reports First Quarter 2008 Financial Results 5Health News:Chem Rx Corporation Reports First Quarter 2008 Financial Results 6Health News:Chem Rx Corporation Reports First Quarter 2008 Financial Results 7Health News:Chem Rx Corporation Reports First Quarter 2008 Financial Results 8Health News:Chem Rx Corporation Reports First Quarter 2008 Financial Results 9Health News:Dermatologists Release Psoriasis Care Guidelines 2
Quatroloc Revision Hip System...
A stable revision design with extensive sizes...
Severe revision options for the knee and hip...
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Medicine Products: